此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢持牌證券商或其他註冊證券機構、銀行經理、律師、執業會計師 或其他專業顧問。 閣下如已將名下的上海昊海生物科技股份有限公司的股份全部售出或轉讓，應立即將本通函連同隨附的代表委任表格送交買方 或承讓人或經手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦不發表任何聲明，並 明確表示，概不對因本通函全部或任何部份內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） (1)董事會2024年度工作報告 (2)監事會2024年度工作報告 (3)2024年度報告 (4)董事、監事2025年度薪酬方案 (5)聘請本公司2025年度財務報告審計機構及內部控制審計機構 (6)2024年度利潤分配方案及授權董事會實施2025年中期分紅 (7)未來三年（20 ...

证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 及 2025 年第一次 H 股类别股东大会 会议资料 二〇二五年六月十日·上海 目 录 关于取消监事会并修订《公司章程》、 为了维护全体股东的合法权益、确保股东大会的正常秩序和议事效率，保证 股东大会的顺利进行，上海昊海生物科技股份有限公司（以下简称"公司"）根 据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）以及《上海昊海生物科技股份有限公司章程》 （以下简 称"《公司章程》"）、 《上海昊海生物科技股份有限公司股东大会议事规则》 《股东大会议事规则》及《董事会议事规则》 上海昊海生物科技股份有限公司 会议须知 （以下 简称"《股东大会议事规则》"）等相关规定，特制定本须知，请全体出席股东大 会的人员自觉遵守。 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、经公司审核后符合参加本次股东大会条件的股东（含股东代理人）、董 事、监事、高级管理人员及其他出席人员方可出席本次会议；公司有权拒 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-024 通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定执行。 不适用 二、 会议审议事项 上海昊海生物科技股份有限公司 关于召开2024年度股东周年大会、2025 年第一次 A 股 类别股东大会及 2025 年第一次 H 股类别股东大会的 （七） 涉及公开征集股东投票权 本次股东大会审议议案及投票股东类型 （一）2024 年度股东周年大会 投票股东类型 序号 议案名称 全体股东 非 ...

证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2024 年度股东周年大会、 2025 年第一次 A 股类别股东大会 及 2025 年第一次 H 股类别股东大会 会议资料 二〇二五年六月十日·上海 1 | 会议须知 . | | --- | | 会议议程 | | 关于公司董事会 2024 年度工作报告的议案 . | | 关于公司监事会 2024年度工作报告的议案 | | 关于公司 2024 年年度报告的议案 . | | 关于公司董事、监事 2025 年薪酬计划的议案 | | 关于聘请公司 2025 年度财务报告审计机构及内部控制审计机构的议案 20 | | 关于公司 2024 年度利润分配预案的议案 | | 关于提请股东大会授权董事会进行 2025 年中期分红的议案 23 | | 关于公司未来三年(2025年-2027年)股东分红回报规划的议案 . | | 关于修订《独立董事工作细则》的议案 | | 关于取消监事会并修订《公司章程》、《股东大会议事规则》及《董事会议事规则》 | | 的议案 | | 关于授予董事会回购 H 股的一般性授权的议案 31 | | 关于选举公司第六届董事会非独 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第 2 頁 共 9 頁 v 1.3.0 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫 ...

Core Viewpoint - The investigation of insider trading involving the controlling shareholder of Haohai Biological Technology has raised concerns about the company's future performance and governance, despite the company's efforts to distance itself from the allegations [1][2][3]. Company Overview - Haohai Biological Technology, founded in 2007 by Jiang Wei, has established a significant presence in the medical absorbable biomaterials sector, particularly in hyaluronic acid products [2][6]. - Jiang Wei and his wife, You Jie, are the largest shareholders, holding 28.53% and 17.29% of the shares, respectively, as of the latest quarterly report [3][4]. Financial Performance - In 2024, Haohai Biological reported revenues of 2.698 billion yuan, a slight increase of 1.64% year-on-year, with a net profit of 420 million yuan, up 1.04% [8][11]. - The medical aesthetics and wound care segment has become the largest revenue source, surpassing the ophthalmology segment, which has faced challenges due to centralized procurement policies [7][8]. Market Dynamics - The company's hyaluronic acid products have seen a significant decline in revenue growth, dropping from 95.54% in 2023 to 23.23% in 2024, indicating a shift in market dynamics and increased competition [8][11]. - The overall gross margin for the company decreased from 70.46% to 69.89%, reflecting pressures from price reductions in traditional product lines due to procurement policies [10][11]. Industry Context - The medical aesthetics industry is experiencing a downturn, with competitors like Langzi Co. and Huaxi Biological also reporting revenue declines, indicating a broader market challenge [12][13]. - The rise of alternative materials and negative press surrounding hyaluronic acid products have added to the operational challenges faced by companies in this sector [13].

Core Viewpoint - The company, Haohai Biological Technology, is facing scrutiny as its controlling shareholder, Jiang Wei, has been notified of an investigation by the China Securities Regulatory Commission (CSRC) for suspected insider trading, although the company asserts that this matter is unrelated to its operations [1][3]. Company Overview - Haohai Biological Technology is engaged in the research, production, and sales of medical devices and pharmaceuticals, focusing on four main areas: medical aesthetics and wound care products, ophthalmic products, orthopedic viscoelastic supplements, and anti-adhesion and hemostatic products [3]. Financial Performance - In 2024, the company reported revenues of approximately 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit attributable to shareholders of about 420 million yuan, up 1.04% [5]. - The company's overall gross margin decreased from 70.46% to 69.89% due to significant price reductions in certain products, which offset the growth in high-margin medical aesthetic products [5]. - The medical aesthetics and wound care segment contributed over 40% of the company's revenue, with a year-on-year increase of 13.08%, although this growth rate has slowed compared to the previous year's 41.27% [5][6]. Market Reaction - Following the announcement of the investigation, Haohai Biological Technology's stock opened down 4.31% on May 8, with a closing price of 52.26 yuan per share, reflecting a decline of 1.71% and a total market capitalization of 12.19 billion yuan [4]. - The company's stock has seen a cumulative decline of 71.76% from its peak in July 2021, and the current share price has fallen below its initial public offering price of 89.23 yuan [7]. Future Outlook - The company plans to continue utilizing its own funds to explore advancements in the medical aesthetics, ophthalmology, orthopedics, and surgical fields, seeking to enhance its product portfolio through technology introduction or investment partnerships [7].

Core Viewpoint - The company is facing significant challenges due to the investigation of its controlling shareholder for insider trading, alongside declining performance in key business segments and increasing competition in the industry [1][5][6]. Financial Performance - The company's overall revenue growth has slowed, with 2024 revenue at 2.698 billion (up 1.64% year-on-year) and net profit at 420 million (up 1.04% year-on-year) [2]. - In Q1 2025, revenue dropped to 619 million (down 4.25% year-on-year) and net profit to 90 million (down 7.41% year-on-year) [2]. - R&D expenses decreased significantly by 25.4%, while sales and management expense ratios increased by 0.54 and 1.52 percentage points, respectively [2]. Business Segmentation - The medical aesthetics segment showed weak growth, with 2024 revenue at 1.2 billion (44.38% of total), and hyaluronic acid product revenue at 742 million (up 23.23% year-on-year), but a sharp decline from 95.45% growth in 2023 [3]. - The ophthalmology segment reported revenue of 858 million (down 7.60% year-on-year), with intraocular lens revenue at 328 million (down 14.06% year-on-year), primarily impacted by a 60% price drop from the fourth national procurement [3]. - The orthopedics segment generated revenue of 457 million (down 4.11% year-on-year), with profits affected by price declines from provincial procurement for sodium hyaluronate injections [4]. Dividend and Market Concerns - The company's high dividend payouts have raised market concerns, with the controlling shareholder couple receiving approximately 344 million in cash dividends from 2019 to 2024, and the 2024 dividend accounting for 54.92% of net profit [4]. Industry Risks - The investigation into the controlling shareholder poses risks, including potential stock freezes or selling restrictions, which could undermine market confidence and highlight governance issues due to concentrated ownership [5][6]. - The company faces intense competition in the medical aesthetics sector, with rivals like Huaxi Biological and Aimeike, and pressure from new technologies impacting traditional markets [6]. - The normalization of centralized procurement is leading to a downward price trend for ophthalmology and orthopedics products, necessitating faster innovation to maintain profit margins [7]. Cash Flow and Asset Quality - Concerns regarding cash flow and asset quality are evident, with accounts receivable at 316 million (75.18% of net profit) and a low inventory turnover rate of 0.39 times [8]. - In Q1 2025, operating cash flow was 86 million, while cash outflow from investment activities was 179 million [8].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | H 股 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

Core Viewpoint - The recent investigation of Jiang Wei, a major shareholder of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading is not expected to significantly impact the company's operations or stock performance [1][2]. Company Overview - Haohai Biological Technology is recognized for its "medical aesthetics + ophthalmology" business model, with a focus on high-margin products such as artificial lenses and medical-grade hyaluronic acid [2][3]. - The company is the first biopharmaceutical firm listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange's Sci-Tech Innovation Board [2]. Financial Performance - Revenue has shown consistent growth from 1.3 billion yuan in 2020 to 2.6 billion yuan in 2024, while net profit increased from 200 million yuan to 400 million yuan during the same period, despite a significant drop in 2022 [2][3]. - In 2024, the company reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, up 1.04% [3]. Market Challenges - The medical aesthetics and ophthalmology sectors are facing increased competition and price reductions due to national procurement policies, leading to stagnation in revenue growth for 2024 [3]. - The medical aesthetics segment has shown signs of growth fatigue, with revenues from medical beauty and wound care products increasing from 460 million yuan in 2021 to 1.2 billion yuan in 2024, but growth rates are declining [3]. Product Development - In July 2024, Haohai Biological Technology received approval for its fourth-generation hyaluronic acid product, Hai Mei Yue Bai, aimed at treating moderate to severe nasolabial folds, positioning it as a potential growth driver in the high-end medical aesthetics market [4]. - The product is priced at 13,800 yuan for 1ml and 19,800 yuan for 2ml, indicating a premium positioning [4]. Recent Performance - In the first quarter of 2024, the company experienced a decline in both revenue and net profit, with revenue at 619 million yuan, down 4.25%, and net profit at approximately 90.31 million yuan, down 7.41% [4].